Industry-Sponsored Research Week

WUSTL School of Medicine and Centene to collaborate on personalized medicine research

By David Schwartz
Published: April 16th, 2019

Washington University School of Medicine in St. Louis and healthcare company Centene have formed a personalized medicine collaboration to accelerate research into treatments for Alzheimer’s disease, breast cancer, diabetes, and obesity.

Under the terms of the deal, Centene will contribute up to $100 million over 10 years to fund research at the School of Medicine’s Personalized Medicine Initiative, which is developing customized disease treatment and prevention for patients. Any products that come out of the collaboration will be commercialized through the ARCH Personalized Medicine Initiative, a joint venture between the School of Medicine and Centene.

The university will contribute its own research and biomedical capabilities — including technologies such as CRISPR — and will involve scientists in the areas of the microbiome, immunomodulatory therapies, cancer genomics, neurodegeneration, cellular reprogramming, chemical biology, and informatics. The university will also use some of the funds to add resources at more than a dozen School of Medicine centers and institutes.

“We will be bringing together world-class resources and intellectual horsepower from every basic and clinical scientific discipline to urgently accelerate the timeline for developing therapies that are more precisely targeted, with aspirations to do so in the next five to seven years,” said David Perlmutter, executive vice chancellor for medical affairs at the School of Medicine. “I believe the most important advances that will evolve from the personalized medicine paradigm will come from harnessing genome engineering technologies to build better model systems of each human disease and utilizing deep genomic and clinical characterization to enable more effective and less expensive clinical trials.”

“We share the goal of helping to improve the health of our communities through research, education and customized treatment for people suffering from chronic illnesses,” added Michael F. Neidorff, chairman and CEO for Centene. “We believe personalized medicine is the path to ensure patients get the targeted health care they need to fight disease, and we look forward to partnering with such a renowned medical school to initially focus on four diseases that impact millions of Americans, including many of our health plan members.”

Source: Washington University School of Medicine in St. Louis

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment